This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hillner, B. E. Articles by Pfister, D. G. Search for Related Content PubMed PubMed Citation Articles by Hillner, B. E. Articles by Pfister, D. G.

American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer

From the American Society of Clinical Oncology, Alexandria, VA.
* Adopted on November 5, 1999, by the American Society of Clinical Oncology.

Address reprint requests to American Society of Clinical Oncology, Health Services Research Department, 225 Reinekers Lane, Suite 650, Alexandria, VA 22314; email guideline{at}asco.org

ABSTRACT

PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of bone metastases in breast cancer and their role relative to other therapies for this condition.

METHODS: An expert multidisciplinary panel reviewed pertinent information from the published literature and meeting abstracts through May 1999. Additional data collected as part of randomized trials and submitted to the United States Food and Drug Administration were also reviewed, and investigators were contacted for more recent information. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the panel. Expert consensus was used if there were insufficient published data. The panel addressed which patients to treat and when in their course of disease, specific drug delivery issues, duration of therapy, management of bony metastases with other therapies, and the public policy implications. The guideline underwent external review by selected physicians, members of the American Society of Clinical Oncology (ASCO) Health Services Research Committee, and the ASCO Board of Directors.

RESULTS: Bisphosphonates have not had an impact on the most reliable cancer end point: overall survival. The benefits have been reductions in skeletal complications, ie, pathologic fractures, surgery for fracture or impending fracture, radiation, spinal cord compression, and hypercalcemia. Intravenous (IV) pamidronate 90 mg delivered over 1 to 2 hours every 3 to 4 weeks is recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy. For women with only an abnormal bone scan but without bony destruction by imaging studies or localized pain, there is insufficient evidence to suggest starting bisphosphonates. Starting bisphosphonates in patients without evidence of bony metastasis, even in the presence of other extraskeletal metastases, is not recommended. Studies of bisphosphonates in the adjuvant setting have yielded inconsistent results. Starting bisphosphonates in patients at any stage of their nonosseous disease, outside of clinical trials, despite a high risk for future bone metastasis, is currently not recommended. Oral bisphosphonates are one of several options which can be used for preservation of bone density in premenopausal patients with treatment-induced menopause. The panel suggests that, once initiated, IV bisphosphonates be continued until evidence of substantial decline in a patient’s general performance status. The panel stresses that clinical judgment must guide what is a substantial decline. There is no evidence addressing the consequences of stopping bisphosphonates after one or more adverse skeletal events. Symptoms in the spine, pelvis, or femur require careful evaluation for spinal cord compression and pathologic fracture before bisphosphonate use and if symptoms recur, persist, or worsen during therapy. The panel recommends that current standards of care for cancer pain, analgesics and local radiation therapy, not be displaced by bisphosphonates. IV pamidronate is recommended in women with pain caused by osteolytic metastasis to relieve pain when used concurrently with systemic chemotherapy and/or hormonal therapy, since it was associated with a modest pain control benefit in controlled trials.

CONCLUSION: Bisphosphonates provide a meaningful supportive but not life-prolonging benefit to many patients with bone metastases from cancer. Further research is warranted to identify clinical predictors of when to start and stop therapy, to integrate their use with other treatments for bone metastases, to identify their role in the adjuvant setting in preventing bone metastases, and to better determine their cost-benefit consequences.

This article has been cited by other articles:

				P. Hadji, J. -J. Body, M. S. Aapro, A. Brufsky, R. E. Coleman, T. Guise, A. Lipton, and M. Tubiana-Hulin Practical guidance for the management of aromatase inhibitor-associated bone loss Ann. Onc., August 1, 2008; 19(8): 1407 - 1416. [Abstract] [Full Text] [PDF]

				C. I. Ripamonti, M. Maniezzo, T. Campa, E. Fagnoni, C. Brunelli, G. Saibene, C. Bareggi, L. Ascani, and E. Cislaghi Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan Ann. Onc., July 22, 2008; (2008) mdn526v1. [Abstract] [Full Text] [PDF]

				S. L. Greenspan, A. Brufsky, B. C. Lembersky, R. Bhattacharya, K. T. Vujevich, S. Perera, S. M. Sereika, and V. G. Vogel Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial J. Clin. Oncol., June 1, 2008; 26(16): 2644 - 2652. [Abstract] [Full Text] [PDF]

				S. H. Giordano, S. Fang, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, and J. S. Goodwin Use of Intravenous Bisphosphonates in Older Women with Breast Cancer Oncologist, May 1, 2008; 13(5): 494 - 502. [Abstract] [Full Text] [PDF]

				S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy J. Dent. Res., November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF]

				F. Daubine, C. Le Gall, J. Gasser, J. Green, and P. Clezardin Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis J Natl Cancer Inst, February 21, 2007; 99(4): 322 - 330. [Abstract] [Full Text] [PDF]

				A. U Buzdar and J. F. Robertson Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer Ann. Pharmacother., September 1, 2006; 40(9): 1572 - 1582. [Abstract] [Full Text] [PDF]

				A. Boucharaba, C.-M. Serre, J. Guglielmi, J.-C. Bordet, P. Clezardin, and O. Peyruchaud The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases PNAS, June 20, 2006; 103(25): 9643 - 9648. [Abstract] [Full Text] [PDF]

				F. Vigna-Taglianti, P. Vineis, A. Liberati, and F. Faggiano Quality of systematic reviews used in guidelines for oncology practice Ann. Onc., April 1, 2006; 17(4): 691 - 701. [Abstract] [Full Text] [PDF]

				Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428. [Abstract] [Full Text] [PDF]

				S. Ruggiero, J. Gralow, R. E. Marx, A. O. Hoff, M. M. Schubert, J. M. Huryn, B. Toth, K. Damato, and V. Valero Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer J. Oncol. Pract, January 1, 2006; 2(1): 7 - 14. [Abstract] [Full Text] [PDF]

				A. Bamias, E. Kastritis, C. Bamia, L. A. Moulopoulos, I. Melakopoulos, G. Bozas, V. Koutsoukou, D. Gika, A. Anagnostopoulos, C. Papadimitriou, et al. Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors J. Clin. Oncol., December 1, 2005; 23(34): 8580 - 8587. [Abstract] [Full Text] [PDF]

				M. D. MELO and G. OBEID Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition J Am Dent Assoc, December 1, 2005; 136(12): 1675 - 1681. [Abstract] [Full Text] [PDF]

				S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang, and M. Namiki The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4-Induced Invasion in Prostate Cancer Cancer Res., October 1, 2005; 65(19): 8818 - 8825. [Abstract] [Full Text] [PDF]

				C. D. Morris and T. A. Einhorn Bisphosphonates in Orthopaedic Surgery J. Bone Joint Surg. Am., July 1, 2005; 87(7): 1609 - 1618. [Abstract] [Full Text] [PDF]

				J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]

				N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi, and S. Takashima Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial J. Clin. Oncol., May 20, 2005; 23(15): 3314 - 3321. [Abstract] [Full Text] [PDF]

				R. E. Coleman Bisphosphonates in breast cancer Ann. Onc., May 1, 2005; 16(5): 687 - 695. [Abstract] [Full Text] [PDF]

				J. Balla The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View Oncologist, May 1, 2005; 10(5): 306 - 308. [Full Text] [PDF]

				J. E. Brown, R. J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, and R. E. Coleman Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors J Natl Cancer Inst, January 5, 2005; 97(1): 59 - 69. [Abstract] [Full Text] [PDF]

				J. R. Berenson Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases Oncologist, January 1, 2005; 10(1): 52 - 62. [Abstract] [Full Text] [PDF]

				F. Rainone Treating Adult Cancer Pain in Primary Care J Am Board Fam Med, November 1, 2004; 17(suppl_1): S48 - S56. [Abstract] [Full Text] [PDF]

				T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567. [Abstract] [Full Text] [PDF]

				R. Rizzoli Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer Ann. Onc., May 1, 2004; 15(5): 700 - 701. [Full Text] [PDF]

				D. Tripathy, M. Lichinitzer, A. Lazarev, S. A. MacLachlan, J. Apffelstaedt, M. Budde, and B. Bergstrom Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann. Onc., May 1, 2004; 15(5): 743 - 750. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer J. Clin. Oncol., December 1, 2003; 21(23): 4277 - 4284. [Abstract] [Full Text] [PDF]

				O. Peyruchaud, C.-M. Serre, R. NicAmhlaoibh, P. Fournier, and P. Clezardin Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity J. Biol. Chem., November 14, 2003; 278(46): 45826 - 45832. [Abstract] [Full Text] [PDF]

				S. Yano, H. Zhang, M. Hanibuchi, T. Miki, H. Goto, H. Uehara, and S. Sone Combined Therapy with a New Bisphosphonate, Minodronate (YM529), and Chemotherapy for Multiple Organ Metastases of Small Cell Lung Cancer Cells in Severe Combined Immunodeficient Mice Clin. Cancer Res., November 1, 2003; 9(14): 5380 - 5385. [Abstract] [Full Text] [PDF]

				J.-J. Body, I. J. Diel, M. R. Lichinitser, E. D. Kreuser, W. Dornoff, V. A. Gorbunova, M. Budde, and B. Bergstrom Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann. Onc., September 1, 2003; 14(9): 1399 - 1405. [Abstract] [Full Text] [PDF]

				J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer BMJ, August 30, 2003; 327(7413): 469. [Abstract] [Full Text] [PDF]

				A. Ibrahim, N. Scher, G. Williams, R. Sridhara, N. Li, G. Chen, J. Leighton, B. Booth, J. V. S. Gobburu, A. Rahman, et al. Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases Clin. Cancer Res., July 1, 2003; 9(7): 2394 - 2399. [Abstract] [Full Text] [PDF]

				P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, and P. Clezardin Bisphosphonates Inhibit Angiogenesis in Vitro and Testosterone-stimulated Vascular Regrowth in the Ventral Prostate in Castrated Rats Cancer Res., November 15, 2002; 62(22): 6538 - 6544. [Abstract] [Full Text] [PDF]

				J. R Gralow Bisphosphonates as adjuvant treatment for breast cancer BMJ, November 9, 2002; 325(7372): 1051 - 1052. [Full Text] [PDF]

				J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736. [Abstract] [Full Text] [PDF]

				S. Goodin, K. V. Rao, and R. S. DiPaola State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer Oncologist, August 1, 2002; 7(4): 360 - 370. [Abstract] [Full Text] [PDF]

				L Groff, E Zecca, F De Conno, C Brunelli, R Boffi, C Panzeri, M Cazzaniga, and C Ripamonti The role of disodium pamidronate in the management of bone pain due to malignancy Palliative Medicine, June 1, 2001; 15(4): 297 - 307. [Abstract] [PDF]

				M. Ozsahin, M. Colleoni, A. Goldhirsch, A. Coates, R. Gelber, and M. Castiglione-Gertsch Bone Metastases in Breast Cancer: How to Prevent? J. Clin. Oncol., May 15, 2001; 19(10): 2764 - 2765. [Full Text] [PDF]

				N. Cherny, C. Ripamonti, J. Pereira, C. Davis, M. Fallon, H. McQuay, S. Mercadante, G. Pasternak, and V. Ventafridda Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report J. Clin. Oncol., May 1, 2001; 19(9): 2542 - 2554. [Abstract] [Full Text] [PDF]

				V.E. Kouloulias, C. Dardoufas, J. Kouvaris, C. Gennatas, and L. Vlahos A Comment From a Radiotherapeutic Point of View Regarding the ASCO Guidelines on the Role of Bisphosphonates in Breast Cancer J. Clin. Oncol., April 1, 2001; 19(7): 2106 - 2106. [Full Text] [PDF]